May 7, 2026

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer, President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Director, Representative Executive Officer, Vice President
Ryosuke Matsui
(TEL. 03-6214-3600)

(Progress of Disclosure Matters) Notice Regarding Completion of Gyre Therapeutics, Inc.'s Acquisition of Cullgen Inc. as a Wholly Owned Subsidiary

GNI Group Ltd. (the "Company") announces that its consolidated subsidiary, Gyre Therapeutics, Inc. (Nasdaq: GYRE, "Gyre"), as announced on March 3, 2026, completed its acquisition of Cullgen Inc. ("Cullgen"), a privately held, clinical-stage biopharmaceutical company, making Cullgen a wholly owned subsidiary of Gyre.
Following the combination, Gyre will become a U.S.- and China-based fully integrated biopharmaceutical company.

- The post-closing combined company has a revenue-producing commercial asset and a robust pipeline of products and product candidates addressing multiple therapeutic areas, with a focus on fibrosis and inflammatory diseases.
- China's innovation engine provides a cost-efficient vehicle for the discovery and early-stage development of targeted protein degraders (TPDs) and degrader-antibody conjugates (DACs).
- The strengthened leadership team in the U.S., combined with the operating presence in China, will support future global growth.

The acquisition was conducted as an all-stock transaction valued at approximately US$300 million. Pursuant to the terms of the definitive agreement, Cullgen became a wholly owned subsidiary of Gyre. In connection with the transaction, Dr. Ying Luo, former Chief Executive Officer of Cullgen, was appointed President and Chief Executive Officer of Gyre. Mr. Ping Zhang will serve as Chairman of the Board of Directors of Gyre.
The combined company will continue to be listed on the Nasdaq Capital Market under the ticker symbol "GYRE."

Dr. Ying Luo, President and Chief Executive Officer of Gyre, commented:
"We are very pleased to move forward as a U.S.- and China-based fully integrated biopharmaceutical company. Through this combination, we have evolved into a company that not only provides ETUARY®, which is already on the market in China for the treatment of lung fibrosis, but also has a broad pipeline ranging from discovery to Phase 3, primarily focused on fibrosis and inflammatory diseases. This includes our lead product candidate, F351, for the treatment of chronic hepatitis B (CHB)-induced liver fibrosis, as well as promising preclinical and clinical programs

including TPDs and DACs."

Mr. Ping Zhang, Chairman of Gyre, commented:
"This combination occurs at a very exciting time for Gyre. The New Drug Application (NDA) for our F351 received priority review designation from the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) in March. We are also exploring the expansion of F351's development in territories outside China, including the U.S.
In addition, we have completed enrollment in the 52-week Phase 3 trial of ETUARY® for pneumoconiosis, and have also enrolled the first patient in the Phase 2/3 clinical trial evaluating ETUARY® for radiation-induced lung injury (RILI), with or without immune checkpoint inhibitor-related pneumonitis (CIP). These developments further strengthen our late-stage inflammatory disease portfolio.
Furthermore, we believe that several promising protein degraders and DACs discovered through Cullgen's innovative discovery platform will further strengthen Gyre's asset portfolio and provide long-term value."

[For Reference] Press Release issued by Gyre Therapeutics, Inc. dated May 4, 2026
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company | Gyre Therapeutics, Inc